China Precision Medicine Push Boosting Genomic Business Forays
As the traditional lines between therapeutics and diagnostics become increasingly blurred, genomic testing is growing apace in China, boosted by the country’s national push into precision medicine. Deals and alliances are coming thick and fast as companies jostle for a slice of the growing pie.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.